SM
Shobhit Mittal
About Shobhit Mittal
Data last updated:
Shobhit Mittal is a Director at Ccft Laboratories Private Limited (since 2022) and Director at Mittal Ayurved Sansthan Private Limited (since 2025). The companies operate in Research & Development and Paper. The 2 current companies with reported revenue have a combined latest revenue of ₹3.68 Cr; the largest is Ccft Laboratories Private Limited at ₹3.58 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 25 Jul 2022 | 2022 | ₹3.58 Cr (FY 2025) | Active | |
| Director | 02 Mar 2025 | 2025 | ₹10.5 Lakh (FY 2025) | Active |
Board colleagues of Shobhit Mittal
| Name | DIN | Company | Designation |
|---|---|---|---|
| Puneet Mittal | 07911425 | Ccft Laboratories Private Limited , Mittal Ayurved Sansthan Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Shobhit Mittal
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shobhit Mittal
Shobhit Mittal currently holds 2 directorships: Ccft Laboratories Private Limited (Director, since 25 Jul 2022, revenue ₹3.58 Cr (FY 2025)); Mittal Ayurved Sansthan Private Limited (Director, since 02 Mar 2025, revenue ₹10.5 Lakh (FY 2025)).
Shobhit Mittal was first appointed on 25 Jul 2022 as Director at Ccft Laboratories Private Limited. The most recent appointment on record is 02 Mar 2025 at Mittal Ayurved Sansthan Private Limited.
The 2 current companies of Shobhit Mittal that report revenue have a combined latest revenue of ₹3.68 Cr: Ccft Laboratories Private Limited ₹3.58 Cr (FY 2025); Mittal Ayurved Sansthan Private Limited ₹10.5 Lakh (FY 2025).
The current boards of Shobhit Mittal's companies include Puneet Mittal (Ccft Laboratories Private Limited).